VISTA is one of the most recently found immunotherapy targets, and while our understanding of its biology in the CNS is limited, it is conceivable to develop novel therapeutic approaches for CNS diseases such as MS by either increasing or reducing its activity [86]. Here, VSIR is linked to myeloid sarcoma.